Published in Bioorg Med Chem on June 19, 2006
Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications. J Med Chem (2012) 1.30
Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs. Eur J Pharm Sci (2010) 1.29
Incorporation of piperazino functionality into 1,3-disubstituted urea as the tertiary pharmacophore affording potent inhibitors of soluble epoxide hydrolase with improved pharmacokinetic properties. J Med Chem (2010) 0.80
Structure-based optimization of the piperazino-containing 1,3-disubstituted ureas affording sub-nanomolar inhibitors of soluble epoxide hydrolase. Medchemcomm (2012) 0.78
Design, synthesis and biological evaluation of 4-benzamidobenzoic Acid hydrazide derivatives as novel soluble epoxide hydrolase inhibitors. Iran J Pharm Res (2014) 0.78
Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature (1999) 4.47
Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci U S A (2005) 4.07
Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res (2000) 3.70
Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension (2002) 3.66
Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. Annu Rev Pharmacol Toxicol (2005) 3.38
Bioactivation of leukotoxins to their toxic diols by epoxide hydrolase. Nat Med (1997) 3.05
Epoxide hydrolases: their roles and interactions with lipid metabolism. Prog Lipid Res (2005) 2.95
Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. Biochem Pharmacol (2002) 2.86
Potent urea and carbamate inhibitors of soluble epoxide hydrolases. Proc Natl Acad Sci U S A (1999) 2.79
Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase. J Lipid Res (2000) 2.70
Design, synthesis, and biological activity of 1,3-disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility. J Med Chem (2004) 2.43
Fluorescent substrates for soluble epoxide hydrolase and application to inhibition studies. Anal Biochem (2005) 2.26
Epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids are potent vasodilators in the canine coronary microcirculation. Circ Res (1998) 2.13
The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc Natl Acad Sci U S A (2005) 2.10
Detoxification of environmental mutagens and carcinogens: structure, mechanism, and evolution of liver epoxide hydrolase. Proc Natl Acad Sci U S A (1999) 1.76
Epoxide hydrolases: biochemistry and molecular biology. Chem Biol Interact (2000) 1.73
Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem (2005) 1.69
Binding of alkylurea inhibitors to epoxide hydrolase implicates active site tyrosines in substrate activation. J Biol Chem (2000) 1.42
Spectrophotometric substrates for cytosolic epoxide hydrolase. Anal Biochem (1994) 1.23
Evaluation of fish models of soluble epoxide hydrolase inhibition. Environ Health Perspect (2001) 1.06
A review of melanocortin receptor small molecule ligands. Peptides (2005) 0.88
Synthesis of [Glu34]human splenin (hSP) and examination of its immunological effect on the reduced B-lymphocytes of uremic patients. Chem Pharm Bull (Tokyo) (1989) 0.78
Mass spectrometry-based metabolomics. Mass Spectrom Rev (2006) 5.23
Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci U S A (2005) 4.07
Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension (2002) 3.66
Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov (2009) 3.46
Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J Clin Invest (2010) 3.41
Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. Annu Rev Pharmacol Toxicol (2005) 3.38
Metabolomics: building on a century of biochemistry to guide human health. Metabolomics (2005) 3.01
Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway. Circ Res (2004) 2.98
Epoxide hydrolases: their roles and interactions with lipid metabolism. Prog Lipid Res (2005) 2.95
Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. Biochem Pharmacol (2002) 2.86
A functional evolutionary approach to identify determinants of nucleosome positioning: a unifying model for establishing the genome-wide pattern. Mol Cell (2012) 2.86
An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension (2005) 2.76
Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J Am Soc Nephrol (2004) 2.59
Regulation of ceramide biosynthesis by TOR complex 2. Cell Metab (2008) 2.57
Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem (2007) 2.45
Design, synthesis, and biological activity of 1,3-disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility. J Med Chem (2004) 2.43
Soluble epoxide hydrolase: a novel therapeutic target in stroke. J Cereb Blood Flow Metab (2007) 2.41
Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Nat Chem Biol (2012) 2.40
Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ Res (2006) 2.33
The simultaneous quantification of cytochrome P450 dependent linoleate and arachidonate metabolites in urine by HPLC-MS/MS. J Lipid Res (2002) 2.32
Fluorescent substrates for soluble epoxide hydrolase and application to inhibition studies. Anal Biochem (2005) 2.26
Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. Proc Natl Acad Sci U S A (2005) 2.25
Epoxyeicosatrienoic acids regulate Trp channel dependent Ca2+ signaling and hyperpolarization in endothelial cells. Arterioscler Thromb Vasc Biol (2007) 2.17
Quantitative profiling method for oxylipin metabolome by liquid chromatography electrospray ionization tandem mass spectrometry. Anal Chem (2009) 2.16
The soluble epoxide hydrolase encoded by EPXH2 is a bifunctional enzyme with novel lipid phosphate phosphatase activity. Proc Natl Acad Sci U S A (2003) 2.13
The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc Natl Acad Sci U S A (2005) 2.10
Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci U S A (2006) 2.07
Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs). Prostaglandins Other Lipid Mediat (2006) 2.03
Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health. Annu Rev Pharmacol Toxicol (2012) 2.01
Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension. Hypertension (2005) 2.01
The soluble epoxide hydrolase as a pharmaceutical target for hypertension. J Cardiovasc Pharmacol (2007) 1.99
Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice. J Biol Chem (2006) 1.95
Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci U S A (2006) 1.95
MicroRNA-7 targets IGF1R (insulin-like growth factor 1 receptor) in tongue squamous cell carcinoma cells. Biochem J (2010) 1.91
Human cytosolic 3alpha-hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily display significant 3beta-hydroxysteroid dehydrogenase activity: implications for steroid hormone metabolism and action. J Biol Chem (2003) 1.90
Inflammatory lipid mediators in adipocyte function and obesity. Nat Rev Endocrinol (2010) 1.87
In vitro biologic activities of the antimicrobials triclocarban, its analogs, and triclosan in bioassay screens: receptor-based bioassay screens. Environ Health Perspect (2008) 1.82
Occurrence of endocrine-disrupting chemicals in indoor dust. Sci Total Environ (2008) 1.81
Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase. Bioorg Med Chem Lett (2006) 1.77
Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: implications for soluble epoxide hydrolase inhibition. Am J Physiol Heart Circ Physiol (2005) 1.76
Naturally occurring monoepoxides of eicosapentaenoic acid and docosahexaenoic acid are bioactive antihyperalgesic lipids. J Lipid Res (2010) 1.76
Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. J Clin Invest (2011) 1.74
Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study. Hum Mol Genet (2006) 1.74
Two microRNA panels to discriminate three subtypes of lung carcinoma in bronchial brushing specimens. Am J Respir Crit Care Med (2012) 1.72
Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain. Life Sci (2006) 1.71
Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathways. Proc Natl Acad Sci U S A (2008) 1.69
Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem (2005) 1.69
MicroRNA-138 suppresses epithelial-mesenchymal transition in squamous cell carcinoma cell lines. Biochem J (2011) 1.67
Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis. Proc Natl Acad Sci U S A (2013) 1.66
The sphingosine-1-phosphate receptor S1PR1 restricts sprouting angiogenesis by regulating the interplay between VE-cadherin and VEGFR2. Dev Cell (2012) 1.66
Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. Am J Physiol Renal Physiol (2009) 1.64
Triclocarban enhances testosterone action: a new type of endocrine disruptor? Endocrinology (2007) 1.63
Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Proc Natl Acad Sci U S A (2007) 1.60
Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation. Br J Pharmacol (2009) 1.60
An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol (2005) 1.59
Ultrabroadband light absorption by a sawtooth anisotropic metamaterial slab. Nano Lett (2012) 1.59
Structure of human epoxide hydrolase reveals mechanistic inferences on bifunctional catalysis in epoxide and phosphate ester hydrolysis. Biochemistry (2004) 1.59
P50 sensory gating ratios in schizophrenics and controls: a review and data analysis. Psychiatry Res (2008) 1.52
Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation. Proc Natl Acad Sci U S A (2002) 1.51
Mir-144 selectively regulates embryonic alpha-hemoglobin synthesis during primitive erythropoiesis. Blood (2008) 1.50
Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model. Biochem Pharmacol (2009) 1.49
Polymorphisms in human soluble epoxide hydrolase. Mol Pharmacol (2003) 1.49
Development of nonsteroidal anti-inflammatory drug analogs and steroid carboxylates selective for human aldo-keto reductase isoforms: potential antineoplastic agents that work independently of cyclooxygenase isozymes. Mol Pharmacol (2004) 1.48
Potent hepatitis B surface antigen response to treatment of hepatitis-B-e-antigen-positive chronic hepatitis B with α-interferon plus a nucleos(t)ide analog. J Gastroenterol Hepatol (2012) 1.46
1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain. J Med Chem (2010) 1.46
Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance. Proc Natl Acad Sci U S A (2011) 1.45
Analgesia mediated by soluble epoxide hydrolase inhibitors is dependent on cAMP. Proc Natl Acad Sci U S A (2011) 1.45
Metabolic profiling of major vitamin D metabolites using Diels-Alder derivatization and ultra-performance liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem (2008) 1.44
Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart. Am J Physiol Heart Circ Physiol (2008) 1.44
Lipoxin generation is related to soluble epoxide hydrolase activity in severe asthma. Am J Respir Crit Care Med (2014) 1.44
Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model. J Cardiovasc Pharmacol (2008) 1.42
The Photorhabdus Pir toxins are similar to a developmentally regulated insect protein but show no juvenile hormone esterase activity. FEMS Microbiol Lett (2005) 1.40
Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy. Proc Natl Acad Sci U S A (2009) 1.40
Revealing the truth about 'trapped rainbow' storage of light in metamaterials. Sci Rep (2012) 1.40
Panax ginseng ginsenoside-Rg2 protects memory impairment via anti-apoptosis in a rat model with vascular dementia. J Ethnopharmacol (2007) 1.39
Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease. Nat Genet (2008) 1.38
Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis. J Pharmacol Exp Ther (2010) 1.38
Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors. Mol Cell Endocrinol (2006) 1.38
Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase. Cell Biochem Biophys (2007) 1.38